Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections
Introduction
Acinetobacter baumannii is an important cause of nosocomial infections in many hospitals. It is difficult to control and difficult to treat due to its high resistance in the environment and its ability to develop resistance to antimicrobials. Bacteraemia is the most significant infection caused by A. baumannii, followed by respiratory tract and surgical wound infections [1]. Clinical manifestations of bloodstream infections (BSIs) by this organism range from transient bacteraemia to fulminant disease with high mortality [2]. Acinetobacter baumannii infections frequently develop in critically ill patients who have significant co-morbidities. High levels of resistance to most classes of antibiotics are common in A. baumannii [3], [4]. Multidrug-resistant Acinetobacter infections have an extremely high crude mortality rate and occur most frequently in severely ill patients [5]. The overall mortality rate associated with A. baumannii bacteraemia is reported to be up to 61.6% [6], [7], [8].
In the treatment of serious bacterial infections, initiation of effective antimicrobial therapy is a strong predictor of mortality. In most cases it is necessary to begin treatment before identification of the causative pathogen [9], [10]. Antibiotic resistance is a major clinical problem in treating Acinetobacter infections. Carbapenems have been preferred for use in serious Acinetobacter infections. However, the prevalence of carbapenem-resistant strains has recently been increasing in hospital settings, especially among critically ill patients, and this situation leads to inappropriate empirical antimicrobial therapy, which results in an unfavourable outcome in patients with Acinetobacter bacteraemia [11]. Nevertheless, the relationship between initial appropriate antimicrobial treatment and clinical outcomes is not well established in patients with A. baumannii bacteraemia.
The aim of the present study was to examine predictors of 30-day mortality and the impact of inappropriate empirical antimicrobial treatment on the mortality of patients with A. baumannii bacteraemia. A retrospective analysis of all episodes of nosocomial A. baumannii bacteraemia seen in Ankara Numune Education and Research Hospital (Ankara, Turkey) over a 3-year period was undertaken.
Section snippets
Study location and patients
This study was conducted at Ankara Numune Education and Research Hospital (Ankara, Turkey), a 1196-bed teaching hospital, over a 3-year period (1 July 2005 to 30 June 2008). All hospitalised patients with a positive blood culture for A. baumannii were included if they were ≥16 years old, the A. baumannii blood culture met the US Centers for Disease Control and Prevention (CDC) criteria for infection [12] and the infection occurred ≥48 h after hospital admission. In patients who had more than one
Results
Between July 2005 and June 2008, 103 patients with nosocomial A. baumannii bacteraemia were included in the study. Of these patients, 38.8% were female and the mean age for all patients was 51 years (range 16–91 years). Acinetobacter baumannii bacteraemia occurred a mean of 24.2 days (range 3–72 days) after hospital admission. The demographic and clinical features of the patients are given in Table 1.
The most common admission diagnoses were neurological disorders (n = 37; 35.9%), solid tumour (n =
Discussion
Over the last 20 years, A. baumannii has emerged as an important nosocomial pathogen. A general trend towards decreased susceptibility to antibiotics has been observed worldwide in the majority of nosocomial strains. Multiple antibiotic resistance threatens the successful treatment of A. baumannii infections [14].
This study was undertaken to evaluate risk factors for mortality and the effect of inappropriate initial antimicrobial therapy on the outcome of patients with A. baumannii bacteraemia.
References (17)
- et al.
Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment
Clin Microbiol Infect
(2002) - et al.
The significance of Acinetobacter baumannii bacteremia compared with Klebsiella pneumoniae bacteremia: risk factors and outcomes
J Hosp Infect
(2006) - et al.
Prospective hospital-wide studies of 505 patients with nosocomial bacteremia in 1997 and 2002
J Hosp Infect
(2006) - et al.
Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis
Am J Med
(2003) - et al.
CDC definitions for nosocomial infections, 1988
Am J Infect Control
(1988) - et al.
Multidrug-resistant Acinetobacter baumannii bacteremia: clinical features, antimicrobial therapy and outcome
Clin Microbiol Infect
(2007) - et al.
Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality
Medicine (Baltimore)
(1995) - et al.
Attributable mortality of Acinetobacter baumannii: no longer a controversial issue
Crit Care
(2007)
Cited by (80)
Emerging bacterial infectious diseases/pathogens vectored by human lice
2023, Travel Medicine and Infectious DiseaseA Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections
2020, ChestCitation Excerpt :The most common methods used to assess severity of illness were the Charlson Comorbidity Index score (17 studies, scores ranging from 1.9 to 7), and the Acute Physiology and Chronic Health Evaluation (APACHE) score (10 studies, scores ranging from 13.3 to 24.7; e-Table 3). Nineteen studies compared mortality in patients without delay in receiving appropriate therapy with that of patients who experienced delay.15,18,20-22,24,25,27-36,43,48 In total, 2,546 patients experienced delayed appropriate antibiotic therapy and 6,778 did not.
Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis
2019, American Journal of Infection ControlCitation Excerpt :Our results clearly demonstrate that an inappropriate antimicrobial therapy can influence the survival rate in CRAB infections. Considerable studies have found that empirical therapy was more critical than definitive therapy in patients with CRAB infections and that alteration of therapy to an appropriate treatment after the available blood culture results did not have a significant effect on outcome.12,39 All of these findings should be considered when choosing empirical antimicrobial therapy, and in hospitals with a high incidence of CRAB, use of more aggressive initial antimicrobial therapy, including colistin, may be an option.
Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia
2018, International Journal of Antimicrobial AgentsCitation Excerpt :Alteration of therapy to an appropriate treatment after the available blood culture results did not have a significant effect on outcome. These findings are in line with previous studies [28]. The effects of inappropriate antimicrobial therapy have been found to be less detrimental in patients who are not severely ill.